Peter P Luk1, James Wykes2, Christina I Selinger1, Rafael Ekmejian3, Jessica Tay3, Kan Gao2, Timothy J Eviston2, Trina Lum1, Sandra A O'Toole4, Jonathan R Clark5, Ruta Gupta6. 1. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia. 2. The Sydney Head and Neck Cancer Institute, Sydney, Australia. 3. University of New South Wales, Sydney, Australia. 4. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia; Central Clinical School, The University of Sydney, Sydney, Australia; Chris O'Brien Lifehouse, Sydney, Australia. 5. The Sydney Head and Neck Cancer Institute, Sydney, Australia; University of New South Wales, Sydney, Australia; Central Clinical School, The University of Sydney, Sydney, Australia; Chris O'Brien Lifehouse, Sydney, Australia. 6. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia; Central Clinical School, The University of Sydney, Sydney, Australia; Chris O'Brien Lifehouse, Sydney, Australia. Electronic address: Ruta.Gupta@sswahs.nsw.gov.au.
Abstract
OBJECTIVE: Mucoepidermoid carcinoma (MEC) is the most common salivary gland malignancy, with a proportion harboring MAML2 rearrangement. This study evaluates the diagnostic and prognostic utility of MAML2 rearrangement in MEC. STUDY DESIGN: Salivary gland malignancies at a single institution (1989-2014) were reviewed to identify MECs. Histopathologic evaluation, immunohistochemistry, and fluorescent in situ hybridization (FISH) were performed. RESULTS: Forty-one cases of MEC were identified, with mean age of 47 years and mean tumor size of 21 mm. Seven locoregional recurrences and five MEC-related deaths were seen over a 22-year follow-up period. Thirty-eight cases were suitable for FISH, and 31 (82%) cases were positive for MAML2 rearrangement, including the oncocytic and clear cell variants of MEC. FISH was negative in the morphologic mimics of MEC. MAML2 rearrangement was significantly associated with longer survival. CONCLUSIONS: MAML2 rearrangement is common and specific for MEC, which makes it a useful diagnostic tool. MAML2 rearrangement also predicts a favorable prognosis.
OBJECTIVE:Mucoepidermoid carcinoma (MEC) is the most common salivary gland malignancy, with a proportion harboring MAML2 rearrangement. This study evaluates the diagnostic and prognostic utility of MAML2 rearrangement in MEC. STUDY DESIGN: Salivary gland malignancies at a single institution (1989-2014) were reviewed to identify MECs. Histopathologic evaluation, immunohistochemistry, and fluorescent in situ hybridization (FISH) were performed. RESULTS: Forty-one cases of MEC were identified, with mean age of 47 years and mean tumor size of 21 mm. Seven locoregional recurrences and five MEC-related deaths were seen over a 22-year follow-up period. Thirty-eight cases were suitable for FISH, and 31 (82%) cases were positive for MAML2 rearrangement, including the oncocytic and clear cell variants of MEC. FISH was negative in the morphologic mimics of MEC. MAML2 rearrangement was significantly associated with longer survival. CONCLUSIONS: MAML2 rearrangement is common and specific for MEC, which makes it a useful diagnostic tool. MAML2 rearrangement also predicts a favorable prognosis.
Authors: Robert O Greer; Jeffrey Eskendri; Paul Freedman; Moni Ahmadian; Aline Murakami-Walter; Marileila Varella-Garcia Journal: J Oral Pathol Med Date: 2017-11-27 Impact factor: 4.253
Authors: Nicole A Cipriani; Jonathan J Lusardi; James McElherne; Alexander T Pearson; Andrea D Olivas; Carrie Fitzpatrick; Mark W Lingen; Elizabeth A Blair Journal: Am J Surg Pathol Date: 2019-07 Impact factor: 6.394
Authors: Peter P Luk; Christina I Selinger; Wendy A Cooper; Annabelle Mahar; Carsten E Palme; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta Journal: Head Neck Pathol Date: 2018-11-22
Authors: Justin Bubola; Christina M MacMillan; Elizabeth G Demicco; Rose A Chami; Catherine T-S Chung; Iona Leong; Paula Marrano; Zeynep Onkal; David Swanson; Brandon M Veremis; Ilan Weinreb; Lei Zhang; Cristina R Antonescu; Brendan C Dickson Journal: Genes Chromosomes Cancer Date: 2021-07-08 Impact factor: 4.263